AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable Bone Grafting Solution in Spine Procedures

March 4, 2020 GMT

IRVINE, Calif.--(BUSINESS WIRE)--Mar 4, 2020--

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon TM moldable bone grafting product.

The expanded indication clears Agilon for use in posterolateral spine procedures when mixed with autograft.

Biogennix designed Agilon to address surgeon demand for a collagen-enhanced product, complementing the company’s existing flagship products, Morpheus TM and osteoSPAN TM. Agilon, which received initial 510(k) marketing clearance last year, contains a high purity, type 1 fibrillar bovine collagen, which provides a site for cell attachment, migration, proliferation, and differentiation. The added collagen also enhances the material handling properties of Agilon.

Agilon is also the latest of Biogennix’s products to contain TrelCor TM technology, a proprietary material engineered to provide the optimal chemistry and architecture for bone healing. TrelCor technology, which also serves as the foundation for Morpheus and osteoSPAN, mimics human cancellous bone by providing full interconnected porosity within naturally-sourced calcium phosphate/calcium carbonate composite (CP/CC) granules.

“Receiving the spine indication for Agilon is exciting news and enables us to make the product available to spine surgeons throughout the US,” said Biogennix V.P. of Sales and Business Development, Scott Bauccio. “Agilon is a superb product with excellent handling properties that we know the spine surgery community wants. Based on the enthusiastic feedback we’ve received from surgeons and distributors since the product launched last year, we anticipate Agilon to be a significant addition to our product offering for spine procedures.”

Biogennix is ramping up national distribution for Agilon, which is available in three optimized sizes: 3cc, 6cc, and 12cc. Agilon requires no hydration prior to use and to date is the only collagen-enhanced synthetic bone graft that comes packaged in an open-barrel syringe, providing the utmost convenience and ease of use for surgeons and OR staff.

Biogennix designs, manufactures and distributes all of its products from its Irvine-based facilities.

Biogennix ® is a fully-integrated osteobiologics company headquartered in Irvine which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures. Biogennix is committed to advancing technology behind natural bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence. Learn more at biogennix.com.

Note to media: photos of Agilon are available upon request.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200304005755/en/

Media Contact: Paul Williams, 310-569-0023,paul@medialinecommunications.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY FDA HEALTH SURGERY

SOURCE: Biogennix

Copyright Business Wire 2020.

PUB: 03/04/2020 03:02 PM/DISC: 03/04/2020 03:02 PM

http://www.businesswire.com/news/home/20200304005755/en